Detalhe da pesquisa
1.
COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study.
J Neurol Neurosurg Psychiatry
; 95(4): 342-347, 2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37857497
2.
Perspectives on Neuromyelitis Optica Spectrum Disorders, the Narrative Medicine contribution to care.
Neurol Sci
; 45(4): 1589-1597, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37919441
3.
Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.
Eur J Neurol
; 30(9): 2859-2864, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37227923
4.
Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis.
Ann Neurol
; 89(5): 1011-1022, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33598931
5.
Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports.
Neurol Sci
; 42(Suppl 1): 9-13, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33904006
6.
Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model.
Hum Mol Genet
; 23(2): 342-54, 2014 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24006477
7.
Pluripotent stem cell-based models of spinal muscular atrophy.
Mol Cell Neurosci
; 64: 44-50, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25511182
8.
Stem cell transplantation for amyotrophic lateral sclerosis: therapeutic potential and perspectives on clinical translation.
Cell Mol Life Sci
; 71(17): 3257-68, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24699704
9.
Molecular, genetic and stem cell-mediated therapeutic strategies for spinal muscular atrophy (SMA).
J Cell Mol Med
; 18(2): 187-96, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24400925
10.
Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.
Cell Mol Life Sci
; 70(23): 4585-602, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23775131
11.
Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy.
Front Neurol
; 15: 1379712, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38638312
12.
Fast but not furious: Rapid ocrelizumab infusion as a strategy to optimize multiple sclerosis patients' management.
J Neurol Sci
; 457: 122897, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38278095
13.
Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
J Neurol
; 271(1): 340-354, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37715789
14.
Direct reprogramming of human astrocytes into neural stem cells and neurons.
Exp Cell Res
; 318(13): 1528-41, 2012 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22426197
15.
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
J Neurol
; 270(7): 3553-3564, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37027018
16.
Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.
J Neurol
; 270(4): 1835-1842, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36795147
17.
Impact of immunotherapies on COVID-19 outcomes in multiple sclerosis patients.
Expert Rev Clin Immunol
; 18(5): 495-512, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35395927
18.
Rehabilitative of COVID-19 patients with acute lower extremity Ischemia and amputation.
J Rehabil Med
; 52(9): jrm00094, 2020 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32720698
19.
Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
J Neurol
; 271(4): 1663-1667, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153549
20.
Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
J Neurol
; 271(6): 3678-3681, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38564055